Download PDF
Semin Liver Dis 2022; 42(03): 341-361
DOI: 10.1055/a-1886-5909
Review Article

Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease

Mauricio Garcia-Saenz-de-Sicilia
1   Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri
,
Lolwa Al-Obaid
1   Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri
,
Dempsey L. Hughes
2   Division of Gastroenterology, Hepatology and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
,
Andrés Duarte-Rojo
2   Division of Gastroenterology, Hepatology and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints


Abstract

Efficient and thorough care of hospitalized patients with advanced chronic liver disease is of utter importance to improve outcomes and optimize quality of life. This requires understanding current evidence and best practices. To facilitate focus on up-to-date knowledge and a practical approach, we have created the HEPA-ROUNDS mnemonic while outlining a practical review of the literature with critical appraisal for the busy clinician. The HEPA-ROUNDS mnemonic provides a structured approach that incorporates critical concepts in terms of prevention, management, and prognostication of the most common complications frequently encountered in patients with advanced chronic liver disease. In addition, implementing the HEPA-ROUNDS mnemonic can facilitate education for trainees and staff caring for patients with advanced chronic liver disease.

Keywords

Advanced Chronic Liver Disease - cirrhosis - hepatorenal syndrome - hyponatremia - albumin - prophylaxis

Authors' Contributions

Mauricio Garcia-Saenz-de-Sicilia, Lolwa Al-Obaid, Dempsey Hughes, and Andres Duarte-Rojo contributed with writing and editing of the manuscript. Mauricio Garcia-Saenz-de-Sicilia, Dempsey Hughes and Andres Duarte-Rojo also contributed with intellectual design, and approved final version of the manuscript.


Supplementary Material



Publication History

Accepted Manuscript online:
28 June 2022

Article published online:
24 August 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 D'Amico G, Pasta L, Morabito A. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39 (10) 1180-1193
    CrossrefPubMedGoogle Scholar
  • 2 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
    Google Scholar
  • 3 O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology 2019; 157 (01) 34-43.e1
    Google Scholar
  • 4 Zermatten MG, Fraga M, Moradpour D. et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. Hepatology 2020; 71 (06) 2135-2148
    Google Scholar
  • 5 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
    Google Scholar
  • 6 Lisman T, Bongers TN, Adelmeijer J. et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (01) 53-61
    Google Scholar
  • 7 Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59 (02) 265-270
    CrossrefPubMedGoogle Scholar
  • 8 Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94 (10) 2801-2803
    CrossrefPubMedGoogle Scholar
  • 9 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117 (01) 139-148
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. J Hepatol 2017; 66 (06) 1313-1326
    CrossrefPubMedGoogle Scholar
  • 11 Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31 (03) 366-374
    CrossrefPubMedGoogle Scholar
  • 12 Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res 2014; 134 (06) 1220-1223
    CrossrefPubMedGoogle Scholar
  • 13 Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA technical review on coagulation in cirrhosis. Gastroenterology 2021; 161 (05) 1630-1656
    CrossrefPubMedGoogle Scholar
  • 14 Stotts MJ, Davis JPE, Shah NL. Coagulation testing and management in liver disease patients. Curr Opin Gastroenterol 2020; 36 (03) 169-176
    CrossrefPubMedGoogle Scholar
  • 15 Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology 2014; 60 (04) 1442
    CrossrefPubMedGoogle Scholar
  • 16 Harrison MF. The misunderstood coagulopathy of liver disease: a review for the acute setting. West J Emerg Med 2018; 19 (05) 863-871
    CrossrefPubMedGoogle Scholar
  • 17 Somani V, Amarapurkar D, Shah A. Thromboelastography for assessing the risk of bleeding in patients with cirrhosis-moving closer. J Clin Exp Hepatol 2017; 7 (04) 284-289
    CrossrefPubMedGoogle Scholar
  • 18 Segal JB, Dzik WH. Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (09) 1413-1425
    CrossrefPubMedGoogle Scholar
  • 19 Terrault N, Chen YC, Izumi N. et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 2018; 155 (03) 705-718
    Google Scholar
  • 20 Tateishi R, Seike M, Kudo M. et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol 2019; 54 (02) 171-181
    CrossrefPubMedGoogle Scholar
  • 21 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2017; 65 (01) 310-335
    CrossrefPubMedGoogle Scholar
  • 22 Adam EH, Möhlmann M, Herrmann E. et al. Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis. World J Gastroenterol 2020; 26 (17) 2097-2110
    CrossrefPubMedGoogle Scholar
  • 23 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
    CrossrefPubMedGoogle Scholar
  • 24 Seeßle J, Löhr J, Kirchner M, Michaelis J, Merle U. Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and non-ACLF patients. BMC Gastroenterol 2020; 20 (01) 271
    CrossrefPubMedGoogle Scholar
  • 25 Kumar M, Ahmad J, Maiwall R. et al. Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal bleeding: a randomized controlled trial. Hepatology 2020; 71 (01) 235-246
    Google Scholar
  • 26 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63 (02) 566-573
    Google Scholar
  • 27 Vilstrup H, Amodio P, Bajaj J. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60 (02) 715-735
    Google Scholar
  • 28 Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol 2015; 13 (12) 2048-2061
    CrossrefPubMedGoogle Scholar
  • 29 Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs 2019; 79 (Suppl 1): 5-9
    CrossrefPubMedGoogle Scholar
  • 30 Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000; 32 (06) 1035-1038
    CrossrefPubMedGoogle Scholar
  • 31 Bajaj JS, Lauridsen M, Tapper EB. et al. Important unresolved questions in the management of hepatic encephalopathy: an ISHEN consensus. Am J Gastroenterol 2020; 115 (07) 989-1002
    CrossrefPubMedGoogle Scholar
  • 32 Hanna A, Gill I, Imam Z, Halalau A, Jamil LH. Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy. BMJ Open Gastroenterol 2021; 8 (01) 8
    CrossrefPubMedGoogle Scholar
  • 33 Rose CF. What's new in our understanding of the pathogenesis of hepatic encephalopathy?. Clin Liver Dis (Hoboken) 2017; 10 (02) 29-31
    CrossrefPubMedGoogle Scholar
  • 34 Strauss E, Tramote R, Silva EP. et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39 (06) 542-545
    PubMedGoogle Scholar
  • 35 Rose CF, Amodio P, Bajaj JS. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 2020; 73 (06) 1526-1547
    CrossrefPubMedGoogle Scholar
  • 36 Arroyo V, Moreau R, Kamath PS. et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016; 2: 16041
    CrossrefPubMedGoogle Scholar
  • 37 Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med 2020; 382 (22) 2137-2145
    CrossrefPubMedGoogle Scholar
  • 38 Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 2014; 174 (11) 1727-1733
    CrossrefPubMedGoogle Scholar
  • 39 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 40 Bureau C, Thabut D, Jezequel C. et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med 2021; 174 (05) 633-640
    CrossrefPubMedGoogle Scholar
  • 41 Caraceni P, Vargas V, Solà E. et al; Liverhope Consortium. The use of rifaximin in patients with cirrhosis. Hepatology 2021; 74 (03) 1660-1673
    CrossrefPubMedGoogle Scholar
  • 42 Gluud LL, Dam G, Les I. et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017; 5: CD001939
    PubMedGoogle Scholar
  • 43 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 2018; 5: CD012410
    PubMedGoogle Scholar
  • 44 Jain A, Sharma BC, Mahajan B. et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology 2022; 75 (05) 1194-1203
    CrossrefPubMedGoogle Scholar
  • 45 Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28 (01) 26-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Biggins SW, Angeli P, Garcia-Tsao G. et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (02) 1014-1048
    CrossrefPubMedGoogle Scholar
  • 47 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
    CrossrefPubMedGoogle Scholar
  • 48 Kanwal F, Tapper EB, Ho C. et al. Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2019; 69 (04) 1787-1797
    CrossrefPubMedGoogle Scholar
  • 49 Fernández J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 2016; 63 (06) 2019-2031
    CrossrefPubMedGoogle Scholar
  • 50 Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E. et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. J Hepatol 2021; 75 (02) 342-350
    CrossrefPubMedGoogle Scholar
  • 51 Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29 (06) 1655-1661
    CrossrefPubMedGoogle Scholar
  • 52 Hou MC, Lin HC, Liu TT. et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39 (03) 746-753
    CrossrefPubMedGoogle Scholar
  • 53 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34 (05) 509-518
    CrossrefPubMedGoogle Scholar
  • 54 Fernández J, Ruiz del Arbol L, Gómez C. et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
    CrossrefPubMedGoogle Scholar
  • 55 Llach J, Rimola A, Navasa M. et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16 (03) 724-727
    CrossrefPubMedGoogle Scholar
  • 56 Fernández J, Navasa M, Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133 (03) 818-824
    CrossrefPubMedGoogle Scholar
  • 57 Moreau R, Elkrief L, Bureau C. et al; NORFLOCIR Trial Investigators. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 2018; 155 (06) 1816-1827.e9
    CrossrefPubMedGoogle Scholar
  • 58 Yim HJ, Suh SJ, Jung YK. et al. Daily norfloxacin vs. weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol 2018; 113 (08) 1167-1176
    CrossrefPubMedGoogle Scholar
  • 59 Lontos S, Shelton E, Angus PW. et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014; 15 (05) 260-267
    CrossrefPubMedGoogle Scholar
  • 60 Komolafe O, Roberts D, Freeman SC. et al. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD013125
    PubMedGoogle Scholar
  • 61 Facciorusso A, Papagiouvanni I, Cela M, Buccino VR, Sacco R. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int 2019; 39 (08) 1448-1458
    CrossrefPubMedGoogle Scholar
  • 62 Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther 2017; 46 (11-12): 1029-1036
    CrossrefPubMedGoogle Scholar
  • 63 Wang W, Yang J, Liu C. et al. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. Eur J Gastroenterol Hepatol 2019; 31 (08) 905-910
    CrossrefPubMedGoogle Scholar
  • 64 Assem M, Elsabaawy M, Abdelrashed M. et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int 2016; 10 (02) 377-385
    CrossrefPubMedGoogle Scholar
  • 65 Hanouneh MA, Hanouneh IA, Hashash JG. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46 (08) 709-715
    CrossrefPubMedGoogle Scholar
  • 66 Ginés P, Rimola A, Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4, Pt 1): 716-724
    CrossrefPubMedGoogle Scholar
  • 67 Piroth L, Pechinot A, Di Martino V. et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis 2014; 14: 287
    CrossrefPubMedGoogle Scholar
  • 68 Mücke MM, Mücke VT, Graf C. et al. Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis. Clin Transl Gastroenterol 2020; 11 (08) e00223
    CrossrefPubMedGoogle Scholar
  • 69 Mücke MM, Mayer A, Kessel J. et al. Quinolone and multidrug resistance predicts failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis 2020; 70 (09) 1916-1924
    CrossrefPubMedGoogle Scholar
  • 70 Elfert A, Abo Ali L, Soliman S, Ibrahim S, Abd-Elsalam S. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016; 28 (12) 1450-1454
    CrossrefPubMedGoogle Scholar
  • 71 Piano S, Fasolato S, Salinas F. et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2016; 63 (04) 1299-1309
    CrossrefPubMedGoogle Scholar
  • 72 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
    CrossrefPubMedGoogle Scholar
  • 73 Ferraioli G, Wong VW, Castera L. et al. Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol 2018; 44 (12) 2419-2440
    CrossrefPubMedGoogle Scholar
  • 74 Vizzutti F, Arena U, Romanelli RG. et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45 (05) 1290-1297
    CrossrefPubMedGoogle Scholar
  • 75 Duarte-Rojo A, Heimbach JK, Borja-Cacho D. et al. Usefulness of controlled attenuation parameter and liver stiffness measurement for the identification of extended-criteria donors and risk-assessment in liver transplantation. Transplantation 2022; 106 (02) 318-327
    CrossrefPubMedGoogle Scholar
  • 76 Berzigotti A, Seijo S, Arena U. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144 (01) 102-111.e1
    CrossrefPubMedGoogle Scholar
  • 77 Shi KQ, Fan YC, Pan ZZ. et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013; 33 (01) 62-71
    CrossrefPubMedGoogle Scholar
  • 78 Procopet B, Berzigotti A, Abraldes JG. et al. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol 2015; 62 (05) 1068-1075
    CrossrefPubMedGoogle Scholar
  • 79 Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical treatment for portal hypertension?. Lancet 1980; 2 (8187): 180-182
    CrossrefPubMedGoogle Scholar
  • 80 Mauro E, Gadano A. What's new in portal hypertension?. Liver Int 2020; 40 (Suppl 1): 122-127
    CrossrefPubMedGoogle Scholar
  • 81 Thabut D, Bureau C, Layese R. et al; ANRS CO12 CirVir Group. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 2019; 156 (04) 997-1009.e5
    CrossrefPubMedGoogle Scholar
  • 82 Tripathi D, Ferguson JW, Kochar N. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009; 50 (03) 825-833
    CrossrefPubMedGoogle Scholar
  • 83 Hwang JH, Shergill AK, Acosta RD. et al; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 2014; 80 (02) 221-227
    CrossrefPubMedGoogle Scholar
  • 84 Villanueva C, Albillos A, Genescà J. et al. β Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393 (10181): 1597-1608
    CrossrefPubMedGoogle Scholar
  • 85 Sersté T, Francoz C, Durand F. et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55 (04) 794-799
    CrossrefPubMedGoogle Scholar
  • 86 Kalambokis GN, Christodoulou D, Baltayiannis G, Christou L. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites. Hepatology 2016; 64 (05) 1806-1808
    CrossrefPubMedGoogle Scholar
  • 87 Mandorfer M, Bota S, Schwabl P. et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146 (07) 1680-1690.e1
    CrossrefPubMedGoogle Scholar
  • 88 Facciorusso A, Roy S, Livadas S. et al. Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites. Dig Dis Sci 2018; 63 (07) 1737-1746
    CrossrefPubMedGoogle Scholar
  • 89 Onali S, Kalafateli M, Majumdar A. et al. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int 2017; 37 (09) 1334-1344
    CrossrefPubMedGoogle Scholar
  • 90 Calès P, Bertrais S, Boursier J, Fouchard I, Oberti F. SNIFF 16 Group. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. Liver Int 2021; 41 (01) 168-179
    CrossrefPubMedGoogle Scholar
  • 91 Scheiner B, Parada-Rodriguez D, Bucsics T. et al. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017; 52 (09) 1008-1015
    PubMedGoogle Scholar
  • 92 Chirapongsathorn S, Valentin N, Alahdab F. et al. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14 (08) 1096-1104.e9
    CrossrefPubMedGoogle Scholar
  • 93 Bhutta AQ, Garcia-Tsao G, Reddy KR. et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 2018; 47 (01) 78-85
    CrossrefPubMedGoogle Scholar
  • 94 Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C. et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol 2020; 73 (06) 1404-1414
    CrossrefPubMedGoogle Scholar
  • 95 Thevenot T, Mouhat B, Cervoni JP, Chopard R. The dual role of non-selective beta-blockers in cirrhotic patients: How do we know when Dr Jekyll turns into Mr Hyde?. Liver Int 2021; 41 (05) 1166-1167
    CrossrefPubMedGoogle Scholar
  • 96 Bernardi M, Angeli P, Claria J. et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020; 69 (06) 1127-1138
    CrossrefPubMedGoogle Scholar
  • 97 Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018; 38 (04) 570-580
    CrossrefPubMedGoogle Scholar
  • 98 Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339 (08) 533-541
    CrossrefPubMedGoogle Scholar
  • 99 Pozzi M, Osculati G, Boari G. et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106 (03) 709-719
    CrossrefPubMedGoogle Scholar
  • 100 Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113 (02) 579-586
    CrossrefPubMedGoogle Scholar
  • 101 European Association for the Study of the Liver, Electronic address, easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
    CrossrefPubMedGoogle Scholar
  • 102 Ginès A, Fernández-Esparrach G, Monescillo A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111 (04) 1002-1010
    CrossrefPubMedGoogle Scholar
  • 103 Ginés P, Arroyo V, Quintero E. et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93 (02) 234-241
    CrossrefPubMedGoogle Scholar
  • 104 Ginès P, Titó L, Arroyo V. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94 (06) 1493-1502
    CrossrefPubMedGoogle Scholar
  • 105 Tan HK, James PD, Wong F. Albumin may prevent the morbidity of paracentesis-induced circulatory dysfunction in cirrhosis and refractory ascites: a pilot study. Dig Dis Sci 2016; 61 (10) 3084-3092
    CrossrefPubMedGoogle Scholar
  • 106 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11 (02) 123-30.e1
    CrossrefPubMedGoogle Scholar
  • 107 Sort P, Navasa M, Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
    CrossrefPubMedGoogle Scholar
  • 108 Poca M, Concepción M, Casas M. et al. Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2012; 10 (03) 309-315
    CrossrefPubMedGoogle Scholar
  • 109 Dionigi E, Garcovich M, Borzio M. et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol 2017; 112 (04) 588-596
    CrossrefPubMedGoogle Scholar
  • 110 O'Leary JG, Reddy KR, Garcia-Tsao G. et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 2018; 67 (06) 2367-2374
    CrossrefPubMedGoogle Scholar
  • 111 Garcia-Martinez R, Andreola F, Mehta G. et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol 2015; 62 (04) 799-806
    CrossrefPubMedGoogle Scholar
  • 112 Fernández J, Clària J, Amorós A. et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019; 157 (01) 149-162
    CrossrefPubMedGoogle Scholar
  • 113 Thévenot T, Bureau C, Oberti F. et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62 (04) 822-830
    CrossrefPubMedGoogle Scholar
  • 114 Best LM, Freeman SC, Sutton AJ. et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2019; 9: CD013103
    PubMedGoogle Scholar
  • 115 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019; 6: CD004039
    PubMedGoogle Scholar
  • 116 China L, Freemantle N, Forrest E. et al; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021; 384 (09) 808-817
    CrossrefPubMedGoogle Scholar
  • 117 Wong YJ, Qiu TY, Tam YC, Mohan BP, Gallegos-Orozco JF, Adler DG. Efficacy and safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2020; 52 (10) 1137-1142
    CrossrefPubMedGoogle Scholar
  • 118 Weiss E, Paugam-Burtz C, Jaber S. Shock etiologies and fluid management in liver failure. Semin Respir Crit Care Med 2018; 39 (05) 538-545
    Article in Thieme ConnectPubMedGoogle Scholar
  • 119 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350 (22) 2247-2256
    CrossrefPubMedGoogle Scholar
  • 120 Caironi P, Tognoni G, Masson S. et al; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370 (15) 1412-1421
    CrossrefPubMedGoogle Scholar
  • 121 Philips CA, Maiwall R, Sharma MK. et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int 2021; 15 (04) 983-994
    CrossrefPubMedGoogle Scholar
  • 122 Lee TH, Kuo G, Chang CH. et al. Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: an updated systematic review and meta-analysis. PLoS One 2021; 16 (12) e0260312
    CrossrefPubMedGoogle Scholar
  • 123 Caraceni P, Riggio O, Angeli P. et al; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391 (10138): 2417-2429
    CrossrefPubMedGoogle Scholar
  • 124 Caraceni P, Tufoni M, Zaccherini G. et al; ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol 2021; 74 (02) 340-349
    CrossrefPubMedGoogle Scholar
  • 125 Solà E, Solé C, Simón-Talero M. et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 2018; 69 (06) 1250-1259
    CrossrefPubMedGoogle Scholar
  • 126 Tandon P, James MT, Abraldes JG, Karvellas CJ, Ye F, Pannu N. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study. PLoS One 2016; 11 (08) e0160394
    CrossrefPubMedGoogle Scholar
  • 127 Angeli P, Ginès P, Wong F. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62 (04) 968-974
    CrossrefPubMedGoogle Scholar
  • 128 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018; 4 (01) 23
    CrossrefPubMedGoogle Scholar
  • 129 Asrani SK, Kim WR, Heimbach J. et al. Acute tubular necrosis is present in the majority of patients undergoing liver transplantation. Hepatology 2011; 54: 629
    PubMedGoogle Scholar
  • 130 Patidar KR, Kang L, Bajaj JS, Carl D, Sanyal AJ. Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology 2018; 68 (01) 224-233
    CrossrefPubMedGoogle Scholar
  • 131 Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019; 71 (04) 811-822
    CrossrefPubMedGoogle Scholar
  • 132 Huelin P, Piano S, Solà E. et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol Hepatol 2017; 15 (03) 438-445.e5
    CrossrefPubMedGoogle Scholar
  • 133 Huggins JT, Doelken P, Walters C, Rockey DC. Point-of-care echocardiography improves assessment of volume status in cirrhosis and hepatorenal syndrome. Am J Med Sci 2016; 351 (05) 550-553
    CrossrefPubMedGoogle Scholar
  • 134 Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011; 58 (06) 928-938
    CrossrefPubMedGoogle Scholar
  • 135 Sanyal AJ, Boyer TD, Frederick RT. et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther 2017; 45 (11) 1390-1402
    CrossrefPubMedGoogle Scholar
  • 136 Wong F, Pappas SC, Curry MP. et al; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021; 384 (09) 818-828
    CrossrefPubMedGoogle Scholar
  • 137 Palmer P, Waleed M, Abdallah M, Melick L, Singal AK. Efficacy and safety of therapies for type 1 hepatorenal syndrome: a systematic review and meta-analysis. Hepatology 2021; 74: 1188-1189
    PubMedGoogle Scholar
  • 138 El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol 2021; 12: 675948
    CrossrefPubMedGoogle Scholar
  • 139 Escorsell A, Bandi JC, Andreu V. et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120 (01) 161-169
    CrossrefPubMedGoogle Scholar
  • 140 Angeli P, Rodríguez E, Piano S. et al; CANONIC Study Investigators of EASL-CLIF Consortium. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut 2015; 64 (10) 1616-1622
    CrossrefPubMedGoogle Scholar
  • 141 Jalan R, Saliba F, Pavesi M. et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61 (05) 1038-1047
    CrossrefPubMedGoogle Scholar
  • 142 Engelmann C, Thomsen KL, Zakeri N. et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Crit Care 2018; 22 (01) 254
    CrossrefPubMedGoogle Scholar
  • 143 Rosenblatt R, Shen N, Tafesh Z. et al. The North American Consortium for the Study of End-Stage Liver Disease - Acute-on-chronic liver failure score accurately predicts survival: an external validation using a national cohort. Liver Transpl 2020; 26 (02) 187-195
    CrossrefPubMedGoogle Scholar
  • 144 Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int 2015; 9 (03) 355-359
    CrossrefPubMedGoogle Scholar
  • 145 Reddy MS, Rajalingam R, Rela M. Liver transplantation in acute-on-chronic liver failure: lessons learnt from acute liver failure setting. Hepatol Int 2015; 9 (04) 508-513
    CrossrefPubMedGoogle Scholar
  • 146 Kwong AJ, Kim WR, Lake JR. et al. OPTN/SRTR 2019 annual data report: liver. Am J Transplant 2021; 21 (Suppl 2): 208-315
    CrossrefPubMedGoogle Scholar
  • 147 Lucey MR, Terrault N, Ojo L. et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19 (01) 3-26
    CrossrefPubMedGoogle Scholar
  • 148 Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17 (Suppl 3): S1-S9
    CrossrefPubMedGoogle Scholar
  • 149 Charlton M, Levitsky J, Aqel B. et al. International Liver Transplantation Society Consensus Statement on immunosuppression in liver transplant recipients. Transplantation 2018; 102 (05) 727-743
    CrossrefPubMedGoogle Scholar
  • 150 Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on immunosuppression in liver transplantation. Euroasian J Hepatogastroenterol 2019; 9 (02) 96-101
    PubMedGoogle Scholar
  • 151 Siddiqui MB, Patel S, Bhati C. et al. Range of normal serum aminotransferase levels in liver transplant recipients. Transplant Proc 2019; 51 (06) 1895-1901
    CrossrefPubMedGoogle Scholar
  • 152 Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55 (02) 447-454
    CrossrefPubMedGoogle Scholar
  • 153 Mason AL, Montano-Loza AJ. Systematic investigation of elevated cholestatic enzymes during the third posttransplant month. Liver Transpl 2013; 19 (Suppl 2): S23-S30
    CrossrefPubMedGoogle Scholar
  • 154 Demetris AJ, Bellamy C, Hübscher SG. et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant 2016; 16 (10) 2816-2835
    CrossrefPubMedGoogle Scholar
  • 155 Gelb B, Feng S. Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol 2009; 3 (06) 631-647
    CrossrefPubMedGoogle Scholar
  • 156 Demetris AJ, Adeyi O, Bellamy CO. et al; Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44 (02) 489-501
    CrossrefPubMedGoogle Scholar
  • 157 Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15 (12) 1662-1670
    CrossrefPubMedGoogle Scholar
  • 158 Laryea M, Watt KD, Molinari M. et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13 (08) 1109-1114
    CrossrefPubMedGoogle Scholar
  • 159 Chen LS, Lin HC, Hwang SJ, Lee FY, Hou MC, Lee SD. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J Gastroenterol Hepatol 1996; 11 (01) 59-64
    CrossrefPubMedGoogle Scholar
  • 160 Voulgaris T, Karagiannakis D, Siakavellas S. et al. High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. Ann Gastroenterol 2019; 32 (05) 451-456
    PubMedGoogle Scholar
  • 161 Bajaj JS, Acharya C, Fagan A. et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol 2018; 113 (08) 1177-1186
    CrossrefPubMedGoogle Scholar
  • 162 Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10 (04) 422-427
    CrossrefPubMedGoogle Scholar
  • 163 Bajaj JS, Zadvornova Y, Heuman DM. et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104 (05) 1130-1134
    CrossrefPubMedGoogle Scholar
  • 164 Bajaj JS, Ananthakrishnan AN, Hafeezullah M. et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105 (01) 106-113
    CrossrefPubMedGoogle Scholar
  • 165 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36 (09) 866-874
    CrossrefPubMedGoogle Scholar
  • 166 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun 2019; 3 (11) 1510-1519
    CrossrefPubMedGoogle Scholar
  • 167 Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC. et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol 2010; 16 (46) 5869-5873
    CrossrefPubMedGoogle Scholar
  • 168 Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology 2022; 162 (04) 1334-1342
    CrossrefPubMedGoogle Scholar
  • 169 Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J Gastroenterol 2002; 37 (12) 1028-1034
    CrossrefPubMedGoogle Scholar
  • 170 Sundaram V, Lim J, Tholey DM. et al. The Braden scale, a standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation. Liver Transpl 2017; 23 (09) 1153-1160
    CrossrefPubMedGoogle Scholar
  • 171 Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl 2017; 23 (11) 1451-1464
    CrossrefPubMedGoogle Scholar
  • 172 Palmer LB, Kuftinec G, Pearlman M, Green CH. Nutrition in cirrhosis. Curr Gastroenterol Rep 2019; 21 (08) 38
    CrossrefPubMedGoogle Scholar
  • 173 European Association for the Study of the Liver. Electronic Address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172-193
    CrossrefPubMedGoogle Scholar
  • 174 Román E, Poca M, Amorós-Figueras G. et al. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Sci Rep 2021; 11 (01) 20415
    CrossrefPubMedGoogle Scholar
  • 175 Ruiz-Margáin A, Macías-Rodríguez RU, Duarte-Rojo A, Ríos-Torres SL, Espinosa-Cuevas Á, Torre A. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. Dig Liver Dis 2015; 47 (04) 309-314
    CrossrefPubMedGoogle Scholar
  • 176 Ruiz-Margain A, Xie JJ, Roman-Calleja BM. et al. Phase angle from bioelectrical impedance for the assessment of sarcopenia in cirrhosis with or without ascites. Clin Gastroenterol Hepatol 2021; 19 (09) 1941-1949.e2
    CrossrefPubMedGoogle Scholar
  • 177 Venu M, Martin E, Saeian K, Gawrieh S. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. Liver Transpl 2013; 19 (06) 627-633
    CrossrefPubMedGoogle Scholar
  • 178 Lai JC, Tandon P, Bernal W. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (03) 1611-1644
    CrossrefPubMedGoogle Scholar
  • 179 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 2018; 67 (05) 1797-1806
    Google Scholar
  • 180 Addepally NS, George N, Martinez-Macias R, Garcia-Saenz-de-Sicilia M, Kim WR, Duarte-Rojo A. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig Dis Sci 2018; 63 (12) 3498-3508
    CrossrefPubMedGoogle Scholar
  • 181 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022; 76 (06) 1263-1278
    CrossrefPubMedGoogle Scholar
  • 182 Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985; 100 (02) 126-131
    PubMedGoogle Scholar
  • 183 Serper M, Tao SY, Kent DS. et al. Inpatient frailty assessment is feasible and predicts nonhome discharge and mortality in decompensated cirrhosis. Liver Transpl 2021; 27 (12) 1711-1722
    CrossrefPubMedGoogle Scholar
  • 184 Lai JC, Rahimi RS, Verna EC. et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology 2019; 156 (06) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 185 Groff A, Serper M, Tao S, Bloomer PM, Dunn MA, Duarte-Rojo A. Highest level of mobility predicts mortality in hospitalized patients with decompensated cirrhosis. Hepatology 2021; 74: 1218A
    PubMedGoogle Scholar
  • 186 Dunn MA, Kappus MR, Bloomer PM, Duarte-Rojo A, Josbeno DA, Jakicic JM. Wearables, physical activity, and exercise testing in liver disease. Semin Liver Dis 2021; 41 (02) 128-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 187 Yadav A, Chang YH, Carpenter S. et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant 2015; 29 (02) 134-141
    CrossrefPubMedGoogle Scholar
  • 188 Dang TT, Ebadi M, Abraldes JG. et al. The 6-minute walk test distance predicts mortality in cirrhosis: a cohort of 694 patients awaiting liver transplantation. Liver Transpl 2021; 27 (10) 1490-1492
    CrossrefPubMedGoogle Scholar
  • 189 Lin FP, Visina JM, Bloomer PM. et al. Prehabilitation-driven changes in frailty metrics predict mortality in patients with advanced liver disease. Am J Gastroenterol 2021; 116 (10) 2105-2117
    CrossrefPubMedGoogle Scholar
  • 190 Duarte-Rojo A, Bloomer PM, Rogers RJ. et al. Introducing EL-FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. Liver Transpl 2021; 27 (04) 502-512
    CrossrefPubMedGoogle Scholar
  • 191 Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44 (06) 1535-1542
    CrossrefPubMedGoogle Scholar
  • 192 Londoño MC, Guevara M, Rimola A. et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130 (04) 1135-1143
    CrossrefPubMedGoogle Scholar
  • 193 Biggins SW. Use of serum sodium for liver transplant graft allocation: a decade in the making, now is it ready for primetime?. Liver Transpl 2015; 21 (03) 279-281
    CrossrefPubMedGoogle Scholar
  • 194 Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342 (21) 1581-1589
    CrossrefPubMedGoogle Scholar
  • 195 Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. Am J Gastroenterol 2020; 115 (11) 1775-1785
    CrossrefPubMedGoogle Scholar
  • 196 China L, Freemantle N, Forrest E. et al. Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: data from the ATTIRE trial. Am J Gastroenterol 2021; 116 (11) 2292-2295
    CrossrefPubMedGoogle Scholar
  • 197 Sigal SH, Amin A, Chiodo III JA, Sanyal A. Management strategies and outcomes for hyponatremia in cirrhosis in the Hyponatremia Registry. Can J Gastroenterol Hepatol 2018; 2018: 1579508
    CrossrefPubMedGoogle Scholar
  • 198 Pose E, Solà E, Piano S. et al. Limited efficacy of tolvaptan in patients with cirrhosis and severe hyponatremia: real-life experience. Am J Med 2017; 130 (03) 372-375
    CrossrefPubMedGoogle Scholar
  • 199 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260.e4
    CrossrefPubMedGoogle Scholar
  • 200 Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 201 Shatzel J, Dulai PS, Harbin D. et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. J Thromb Haemost 2015; 13 (07) 1245-1253
    CrossrefPubMedGoogle Scholar